Alzheon researchers discover new brain substance, providing possible Alzheimer's therapy pathway

6 August 2018
2019_biotech_test_vial_discovery_big

Alzheon, a privately-held biopharmaceutical company with a focus on Alzheimer's, announced on Monday that researchers had discovered a naturally-occurring substance in the human brain that suppresses the production of a protein linked to the disease.

The substance, which has been named as 3-sulfopropanoic acid (3-SPA), is the primary metabolite of tramiprosate (homotaurine), the active ingredient in Alzheon's ALZ-801. This news comes after extensive research, which Alzheon says has allowed it to come to firm conclusions about the nature of 3-SPA and its role in fighting Alzheimer's disease.

3-SPA inhibits the formation of the neurotoxic beta amyloid (AB) oligomers, the key force behind the escalation of Alzheimer's symptoms. The company reports that 3-SPA levels were up to 12 times greater in Alzheimer's patients taking ALZ-801 than those on placebo.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology